[Potential of personalized antihypertensive therapy]

Area of Science:

• Cardiovascular Genetics
• Pharmacogenomics
• Hypertension Research

Background:

• Genome-wide association (GWA) studies are increasingly used for cardiovascular disease genetics.
• Despite success in identifying risks for myocardial infarction and diabetes, GWA studies for hypertension remain inconclusive.
• Potential reasons for GWA study limitations in hypertension include the small effect of individual single nucleotide polymorphisms (SNPs) and the complexity of hypertension morbidity.

Purpose of the Study:

• To review the challenges and potential solutions in the genetic investigation of hypertension.
• To explore the role of genetic epidemiology and pharmacogenomics in understanding hypertension.
• To discuss the future of personalized antihypertensive therapy based on genetic insights.

Main Methods:

• Review of existing literature on genetic studies in hypertension.
• Analysis of the limitations of traditional GWA studies for complex traits like hypertension.
• Exploration of emerging genetic approaches, including genetic epidemiology and pharmacogenomics.

Main Results:

• GWA studies have identified some SNPs associated with cardiovascular risks but have not yielded definitive results for hypertension.
• Emerging evidence suggests that certain SNPs influence salt sensitivity and response to antihypertensive treatments.
• Genetic factors play a role in individual variability in blood pressure regulation and treatment efficacy.

Conclusions:

• Personalized antihypertensive therapy holds significant potential for improving treatment outcomes.
• Integrating genetic epidemiological and pharmacogenomic approaches is crucial for advancing hypertension research.
• Future research should focus on identifying genetic markers to tailor antihypertensive strategies to individual patients.